A PK and Safety Evaluation of HORIZANT (Gabapentin Enacarbil) in Adolescents With Moderate-to-Severe Primary RLS

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
The primary objective is to assess the pharmacokinetics (PK) of gabapentin following the single-dose administration of HORIZANT (Gabapentin Enacarbil) in adolescents (13 to 17 years of age) diagnosed with moderate-to-severe Primary Restless Legs Syndrome (RLS).
Epistemonikos ID: 00507f745575a3d4669a26702988d201b5fb6c12
First added on: May 12, 2024